Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
Information source: Oncotherapeutics
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Multiple Myeloma
Intervention: Melphalan (Drug); Panobinostat (Drug)
Phase: Phase 1/Phase 2
Status: Completed
Sponsored by: Oncotherapeutics Official(s) and/or principal investigator(s): James R. Berenson, MD, Principal Investigator, Affiliation: Oncotherapeutics
Summary
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing.
Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for
cell growth. Giving melphalan together with panobinostat may kill more cancer cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of melphalan when
given together with panobinostat in treating patients with recurrent multiple myeloma.
Clinical Details
Official title: A Phase I/II Study of Oral Melphalan Combined With LBH589 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Maximum Tolerated Dose (MTD)MTD Overall Response Rate (ORR) and Clinical Benefit Rate (CBR) [ORR= Complete Response (CR) + Very Good Partial Response (VGPR) + Partial Response (PR)]; CBR=ORR + Minimal Response (MR)] Following Treatment With Panobinostat and Melphalan
Secondary outcome: Duration of ResponseTime to Progression
Detailed description:
OBJECTIVES:
Primary
- To establish the maximum tolerated dose (MTD) and determine the dose-limiting
toxicities (DLT) of panobinostat in combination with melphalan in patients with
relapsed or refractory multiple myeloma. (Phase I)
- To determine the dose of this regimen to be used in the Phase II portion of the study.
(Phase I)
- To determine the efficacy as evidenced by the response rate (combined complete
response, very good partial response, partial response, and minimal response) in
patients treated with this regimen. (Phase II)
Secondary
- To obtain preliminary evidence of efficacy of the combination of LBH589 and melphalan
for patients with relapsed or refractory multiple myeloma. (Phase I)
- To determine the safety and tolerability of this regimen in these patients. (Phase II)
- To determine time to disease progression, time to response, and duration of response in
patients treated with this regimen. (Phase II)
- To determine progression-free survival and overall survival of patients treated with
this regimen. (Phase II)
OUTLINE: This is a multicenter, phase I, dose-escalation study followed by a phase II study.
Patients receive oral panobinostat once daily on days 1, 3, 5, 8, 10, and 12 and oral
melphalan once daily on days 1, 3 and 5. Treatment repeats every 28 days for up to 8 courses
in the absence of disease progression or unacceptable toxicity.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion criteria:
- Diagnosis of multiple myeloma, based on the following criteria:
- Major criteria
- Plasmacytomas on tissue biopsy (1)
- Bone marrow plasmacytosis (> 30% plasma cells) (2)
- Monoclonal immunoglobulin (Ig) spike on serum electrophoresis, IgG > 3. 5
g/dL or IgA > 2. 0 g/dL, and kappa or lambda light chain excretion > 1 g/day
on 24-hour urine protein electrophoresis (3)
- Minor Criteria
- Bone marrow plasmacytosis (10-30% plasma cells) (a)
- Monoclonal immunoglobulin present but of lesser magnitude than given under
major criteria (b)
- Lytic bone lesions ©)
- Normal IgM < 50 mg/dL, IgA < 100 mg/dL, or IgG < 600 mg/dL (d)
- Meets any of the following sets of multiple myeloma diagnostic criteria:
- Any two of the major criteria
- Major criterion 1 plus minor criterion b, c, or d
- Major criterion 3 plus minor criterion a or c
- Minor criteria a, b, and c, OR a, b, and d
- Measurable disease, defined as a monoclonal immunoglobulin spike on serum
electrophoresis of ≥ 1 g/dL and/or urine monoclonal immunoglobulin spike of ≥ 200
mg/24 hours, or evidence of lytic bone disease
- Must have received ≥ 1 prior treatment regimen OR refractory to most recent
chemotherapy
- Relapsed following stabilization or response to standard first-line chemotherapy
(e. g., vincristine, doxorubicin hydrochloride, and prednisone or melphalan and
prednisone) or first-line high-dose chemotherapy
- Refractory (i. e., failure to achieve at least complete or partial response or
stable disease) to most recent chemotherapy, whether or not containing systemic
corticosteroids
- Prior treatment with ≤ 4 days of a total of 400 mg of prednisone (or an
equivalent potency of another steroid) for myeloma is not considered a regimen
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Life expectancy > 3 months
- Platelet count ≥ 75 x 10^9/L (≥ 50 x 10^9/L if bone marrow is extensively
infiltrated)
- Absolute neutrophil count ≥ 1. 5 x 10^9/L (≥ 1. 0 x 10^9/L if bone marrow is
extensively infiltrated)
- Aspartate transaminase (AST) and Alanine transaminase (ALT) ≤ 2. 5 times upper limit
of normal (ULN)
- Serum bilirubin ≤ 1. 5 times ULN
- Creatinine clearance ≥ 30 mL/min; creatinine > 10 mL/min and < 30 mL/min due to
significant myelomatous involvement of the kidneys allowed with medical director
approval
- Serum potassium ≥ lower limit of normal (LLN)
- Serum magnesium ≥ LLN
- Serum phosphorus ≥ LLN
- Prior localized radiotherapy
Exclusion criteria:
- Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal
protein, and skin changes (POEMS syndrome)
- Plasma cell leukemia
- Pregnant or nursing females; fertile patients must use effective contraception
- Peripheral neuropathy > grade 2
- Impaired cardiac function or clinically significant cardiac disease (including
congenital long QT syndrome, history or presence of sustained ventricular
tachyarrhythmia; history of ventricular fibrillation or Torsade de Pointes;
bradycardia, defined as heart rate (HR) < 50 beats per minute (bpm) [pacemaker
allowed provided HR ≥ 50 bpm]; corrected QT interval > 450 msec on screening ECG;
left ventricular ejection fraction below normal on screening ECHO or multigated
acquisition (MUGA) scan; right bundle branch block with left anterior hemiblock
(bifascicular block); myocardial infarction or unstable angina within the past 6
months; New York Heart Association class III-IV congestive heart failure;
uncontrolled hypertension; history of labile hypertension; history of poor compliance
with an antihypertensive regimen)
- Impaired gastrointestinal (GI) function or GI disease that may significantly alter
the absorption of panobinostat
- Prior malignancy within the past 5 years except basal cell or squamous cell carcinoma
or carcinoma in situ of the cervix
- Other concurrent severe and/or uncontrolled medical or psychiatric conditions (e. g.,
uncontrolled diabetes or active or uncontrolled infection), including abnormal
laboratory values that could cause unacceptable safety risks or compromise protocol
compliance
- Known positivity for HIV or hepatitis B or C
- Severe hypercalcemia (i. e., serum calcium ≥ 14 mg/dL)
- Significant history of non-compliance to medical regimens or unwillingness or
inability to comply with instructions given by the study staff
- Concurrent medication that risk prolonging the QT interval or inducing Torsades de
Pointes
- Prior panobinostat
- Received chemotherapy, bortezomib, thalidomide, lenalidomide or arsenic trioxide
within 3 wks of enrollment (with the exception of nitrosoureas within 6 wks of
enrollment)
- Received corticosteroids (>10 mg/day prednisone or equivalent) within three weeks
before enrollment.
- Received immunotherapy within < 8 weeks; antibody within < 4 weeks; or radiation
therapy to > 30% of marrow-bearing bone within < 2 weeks prior to starting study
treatment; or who have not yet recovered from side effects of such therapies.
Locations and Contacts
Comprehensive Blood and Cancer Center, Bakersfield, California 93309-0633, United States
James R. Berenson MD, Incorporated, West Hollywood, California 90069, United States
Rocky Mountain Cancer Centers - Denver Midtown, Denver, Colorado 80218, United States
Center for Cancer and Blood Disorders, Bethesda, Maryland 20817, United States
Additional Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date: July 2008
Last updated: April 24, 2014
|